Your browser is no longer supported. Please, upgrade your browser.
Settings
ALVR [NASD]
AlloVir, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own10.70% Shs Outstand61.66M Perf Week-2.47%
Market Cap2.71B Forward P/E- EPS next Y-2.05 Insider Trans-3.61% Shs Float27.46M Perf Month3.53%
Income-69.80M PEG- EPS next Q-0.42 Inst Own36.30% Short Float7.19% Perf Quarter8.26%
Sales- P/S- EPS this Y-192.30% Inst Trans10.68% Short Ratio7.02 Perf Half Y35.17%
Book/sh6.06 P/B6.25 EPS next Y-16.60% ROA- Target Price48.00 Perf Year-
Cash/sh5.29 P/C7.16 EPS next 5Y- ROE- 52W Range18.15 - 48.96 Perf YTD-1.51%
Dividend- P/FCF- EPS past 5Y- ROI51.80% 52W High-22.67% Beta-
Dividend %- Quick Ratio28.40 Sales past 5Y- Gross Margin- 52W Low108.60% ATR3.52
Employees32 Current Ratio28.40 Sales Q/Q- Oper. Margin- RSI (14)42.76 Volatility10.55% 8.72%
OptionableYes Debt/Eq0.00 EPS Q/Q-949.50% Profit Margin- Rel Volume0.68 Prev Close38.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume281.49K Price37.86
Recom1.70 SMA20-8.60% SMA50-8.48% SMA2009.87% Volume191,502 Change-1.35%
Aug-24-20Initiated SVB Leerink Outperform $41
Aug-24-20Initiated Morgan Stanley Overweight $49
Aug-24-20Initiated JP Morgan Overweight $50
Feb-17-21 07:30AM  
Feb-11-21 04:00PM  
07:00AM  
Jan-11-21 01:52PM  
Jan-04-21 07:30AM  
Dec-28-20 11:21PM  
Dec-17-20 07:30AM  
Dec-11-20 12:54PM  
Dec-10-20 01:03PM  
Dec-07-20 04:30PM  
Dec-05-20 11:00AM  
Nov-24-20 07:30AM  
Nov-10-20 07:00AM  
Nov-04-20 01:33PM  
Oct-30-20 06:52AM  
Oct-21-20 07:30AM  
Sep-21-20 06:14AM  
Sep-17-20 09:49AM  
Sep-08-20 04:15PM  
Sep-02-20 07:30AM  
Aug-25-20 07:30AM  
Aug-03-20 04:30PM  
Jul-30-20 08:53AM  
07:32AM  
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAN BEEK JEROEN BChief Commercial OfficerFeb 23Sale39.562,11883,783494,162Feb 23 07:44 PM
Vera JuanDirectorFeb 23Sale39.408,850348,6842,403,764Feb 23 07:44 PM
Leen Ann M.Chief Scientific OfficerFeb 23Sale39.504,199165,8762,471,685Feb 23 07:43 PM
Brenner MalcolmDirectorFeb 23Sale39.478,489335,036968,619Feb 23 07:42 PM
VAN BEEK JEROEN BChief Commercial OfficerFeb 22Sale42.542,800119,118496,280Feb 23 07:44 PM
Vera JuanDirectorFeb 22Sale42.5714,321609,6142,412,614Feb 23 07:44 PM
Leen Ann M.Chief Scientific OfficerFeb 22Sale42.575,706242,8802,475,884Feb 23 07:43 PM
Brenner MalcolmDirectorFeb 22Sale42.5711,423486,246977,108Feb 23 07:42 PM
Hagen Brett RChief Accounting OfficerFeb 22Sale43.1480034,50964,765Feb 23 07:43 PM
VAN BEEK JEROEN BChief Commercial OfficerFeb 19Sale41.714,165173,720499,080Feb 23 07:44 PM
Vera JuanDirectorFeb 19Sale41.7913,233553,0112,426,935Feb 23 07:44 PM
Leen Ann M.Chief Scientific OfficerFeb 19Sale41.757,541314,8682,481,590Feb 23 07:43 PM
Brenner MalcolmDirectorFeb 19Sale41.7811,990500,935988,531Feb 23 07:42 PM
Bornstein Jeffrey SDirectorFeb 18Sale40.4320,583832,1190Feb 23 07:57 PM
Hagen Brett RChief Accounting OfficerFeb 18Sale40.1174129,72465,565Feb 19 08:44 AM
Leen Ann M.Chief Scientific OfficerFeb 18Sale40.812,700110,1942,489,131Feb 19 08:44 AM
Vera JuanDirectorFeb 18Sale40.758,942364,3682,440,168Feb 19 08:41 AM
VAN BEEK JEROEN BChief Commercial OfficerFeb 18Sale40.672,08584,787503,245Feb 19 08:41 AM
Brenner MalcolmDirectorFeb 18Sale40.756,757275,3661,000,521Feb 19 08:38 AM
Vera JuanDirectorFeb 17Sale40.347,460300,9302,449,110Feb 18 09:25 PM
Brenner MalcolmDirectorFeb 17Sale40.455,165208,9251,007,278Feb 18 09:24 PM
Leen Ann M.Chief Scientific OfficerFeb 17Sale40.452,28692,4682,491,831Feb 18 09:22 PM
VAN BEEK JEROEN BChief Commercial OfficerFeb 17Sale40.362,30092,837505,330Feb 18 09:20 PM
Hagen Brett RChief Accounting OfficerFeb 17Sale40.422,32093,76366,306Feb 18 09:18 PM
Vera JuanDirectorFeb 16Sale41.8610,400435,3652,456,570Feb 18 09:25 PM
Brenner MalcolmDirectorFeb 16Sale41.856,220260,3321,012,443Feb 18 09:24 PM
Leen Ann M.Chief Scientific OfficerFeb 16Sale41.883,050127,7332,494,117Feb 18 09:22 PM
VAN BEEK JEROEN BChief Commercial OfficerFeb 16Sale41.863,100129,770507,630Feb 18 09:20 PM
Hagen Brett RChief Accounting OfficerFeb 16Sale41.913,050127,81668,626Feb 18 09:18 PM
Melian AgustinChief Medical OfficerFeb 02Sale41.1954,8492,259,230520,266Feb 04 04:35 PM
VAN BEEK JEROEN BChief Commercial OfficerFeb 02Sale41.1948,9102,014,603510,730Feb 04 04:35 PM
Jovan-Embiricos MoranaDirectorAug 03Buy17.002,900,00049,300,0002,800,000Aug 06 06:06 AM
VAN BEEK JEROEN BChief Commercial OfficerAug 03Buy17.003,00051,000524,640Aug 05 09:55 PM
Brainard DianaDirectorAug 03Buy17.006,300107,1006,300Aug 05 09:42 PM
Atillasoy ErcemSee RemarksAug 03Buy17.003,50059,50078,500Aug 05 09:39 PM